This is the authors' abstract. We don't add key points for this paper.
Virtual screening and molecular docking are widely used computational strategies for drug discovery. Recently, deep learning has emerged as a powerful approach that leverages known pharmacological data to identify compounds with similar bioactive profiles. Here, we developed a new end-to-end pipeline called “D2Screen” (Deep learning and Docking-based Screening) that combines both deep learning and molecular docking. D2Screen exhibits higher accuracy compared with individual deep learning or molecular docking prediction with improved BedROC and EF1% metrics. In a case study on developing antidrug resistant inhibitors against SARS-CoV-2 Mpro, we employed D2Screen to successfully discover a group of noncovalent inhibitors with the most potent compound having the IC50 of 5.9 μM. This inhibitor showed significantly less susceptibility to known drug-resistant Mpro mutations T21I-E166V with a 7.6-fold reduction versus an over 1000-fold reduction of the clinically used drug Nirmatrelvir for COVID-19 treatment.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: